** Shares of drug developer Syndax Pharmaceuticals SNDX.O fall 5% to $14.86
** Co posts Q4 net loss of $94.2 million, compared to $72.5 million a year ago
** Reports Q4 operating expenses of $96.4 million, compared to $77.91 million a year ago
** Co reports Q4 sales of $7.7 mln for its first commercial product, Revuforj, chemically known as revumenib, to treat a type of blood cancer
** Expects to seek regulatory approval for revumenib to treat a type of cancer that starts in bone marrow in Q2 2025
** SNDX's shares have fallen 35% in the last 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.